

03CO 井10

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Yumi Yokoyama et al.

Title:

Filed:

GENETIC MODIFICATION OF ENDOSTATIN

Docket No.:

600.491US2

April 4, 2001

Examiner:

Serial No.: 09/825,765

Due Date: May 15, 2002 Group Art Unit: 1645

**Box Sequence** 

U.S. Patent and Trademark Office

P.O. Box 2327

Arlington, VA 22202

We are transmitting herewith the following attached items (as indicated with an "X"):

A return postcard.

Communication Under 37 C.F.R. 1.821 (1 Page).

Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence

Disclosures (1 Page).

Replacement Copy of the Computer Readable form in ASC II.

Prease consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and prease charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P. Box 2938, Minneapolis, MN 55402 (612-373-6900)

Atty: Janet E. Embretson

Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Box Sequence, U.S. Patent and Trademark Office, P. O. Box 2327, Arlington, VA 22202, on this 154 day of May, 2002.

Name

ħJ

Signature

**Customer Number 21186** 

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

(GENERAL)





## United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER FIRST NAMED APPLICANT FILING/RECEIPT DATE ATTORNEY DOCKET NUMBER 09/825,765

Minneapolis, MN 55402

P.O. Box 2938

Schwegman, Lundberg, Woessner & Kluth, P.A.

04/04/2001

Yumi Yokoyama

600.491US2

CONFIRMATION NO. 3671

**FORMALITIES LETTER** 

OC000000007653282\*

Date Mailed: 03/15/2002

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE